Correlation Between Moleculin Biotech and Crispr Therapeutics

Can any of the company-specific risk be diversified away by investing in both Moleculin Biotech and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Moleculin Biotech and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Moleculin Biotech and Crispr Therapeutics AG, you can compare the effects of market volatilities on Moleculin Biotech and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Moleculin Biotech with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Moleculin Biotech and Crispr Therapeutics.

Diversification Opportunities for Moleculin Biotech and Crispr Therapeutics

-0.5

Correlation Coefficient

Moleculin Biotech  Crispr Therapeutics

Very good diversification

The 3 months correlation between Moleculin and Crispr is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding Moleculin Biotech and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Moleculin Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Moleculin Biotech are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Moleculin Biotech i.e., Moleculin Biotech and Crispr Therapeutics go up and down completely randomly.

Pair Corralation between Moleculin Biotech and Crispr Therapeutics

Given the investment horizon of 90 days Moleculin Biotech is expected to generate 10.2 times less return on investment than Crispr Therapeutics. In addition to that, Moleculin Biotech is 2.71 times more volatile than Crispr Therapeutics AG. It trades about 0.01 of its total potential returns per unit of risk. Crispr Therapeutics AG is currently generating about 0.17 per unit of volatility. If you would invest  3,762  in Crispr Therapeutics AG on May 4, 2025 and sell it today you would earn a total of  1,847  from holding Crispr Therapeutics AG or generate 49.1% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	98.41%
Values	Daily Returns

Moleculin Biotech  vs.  Crispr Therapeutics AG

Moleculin Biotech

Risk-Adjusted Performance

Very Weak

Over the last 90 days Moleculin Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Moleculin Biotech is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Crispr Therapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Crispr Therapeutics AG are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Crispr Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Moleculin Biotech and Crispr Therapeutics

The main advantage of trading using opposite Moleculin Biotech and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Moleculin Biotech position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.

The idea behind Moleculin Biotech and Crispr Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.